Literature DB >> 840321

The role played by the extraneuronal system in the disposition of noradrenaline and adrenaline in vessels.

S Guimarães, M Q Paiva.   

Abstract

The role played by extraneuronal sites in the disposition of noradrenaline and adrenaline was studied in the saphenous vein and in the mesenteric artery of the dog, taking as parameters the influence of blockade of these sites on the sensitivity to and on the time for half-relaxation (t50) (both in oil and in Krebs solution) of these agonists. Preliminary experiments have shown that the t50 values are not significantly changed by the changes in the height of the contraction provided the contraction is caused by the same concentration of the agonist. The results obtained permit us to conclude that in both vessels the removal of amines depends on the concentrations used. In low (0.023 and 0.23 muM) or in moderately high (2.3 muM) concentrations, adrenaline is removed preferentially by extraneuronal sites, whereas noradrenaline "preferred" neuronal sites. The selectivity of adrenaline for extraneuronal sites was present for such low concentrations that a possible physiological role of these sites in the inactivation of circulating adrenaline must be considered. The results obtained by studying the relaxation in oil in Krebs solution and by using cortexone (60 muM) or U-0521 (dihydroxy-2-methyl propiophenone; 0.1 mM) support the view that, at least in the vein, adrenaline may accumulate in extraneuronal cells and diffuse back into the biophase during the relaxation, thereby slowing the latter. Both in the veins and in the arteries noradrenaline was inactivated more rapidly than adrenaline. The difference in the rate of inactivation of these amines, already observed in controls (when all inactivation pathways are operative) became more marked when both neuronal and extraneuronal sites were blocked. The existence of an important pathway not blocked by cocaine + cortexone + iproniazid which may preferentially inactivate noradrenaline cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 840321     DOI: 10.1007/BF00498694

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  21 in total

1.  Factors determining the rate of relaxation of rabbit aortic strips after an exposure to noradrenaline.

Authors:  U Trendelenburg; M Henseling; G Schlör
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-06       Impact factor: 3.000

2.  The uptake and metabolism of 3H-l-and 3H-dl-norepinephrine by intact rabbit aorta and by isolated adventitia and media.

Authors:  J A Levin
Journal:  J Pharmacol Exp Ther       Date:  1974-08       Impact factor: 4.030

3.  Inactivation of endogenous noradrenaline released by electrical stimulation in vitro of dog saphenous vein.

Authors:  F Brandão; S Guimarães
Journal:  Blood Vessels       Date:  1974

4.  Adrenergic receptors in the veins of the dog.

Authors:  S Guimarães; W Osswald
Journal:  Eur J Pharmacol       Date:  1969-01       Impact factor: 4.432

5.  The effect of hydrocortisone on the sensitivity of the isolated nictitating membrane to catecholamines: Relationship to extraneuronal uptake and metabolism.

Authors:  K H Graefe; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  A method for the study of mechanisms of drug disposition in smooth muscle.

Authors:  S Kalsner; M Nickerson
Journal:  Can J Physiol Pharmacol       Date:  1968-09       Impact factor: 2.273

7.  Uptake of noradrenaline by adrenergic nerves, smooth muscle and connective tissue in isolated perfused arteries and its correlation with the vasoconstrictor response.

Authors:  O V Avakian; J S Gillespie
Journal:  Br J Pharmacol Chemother       Date:  1968-01

8.  Studies on the potentiation of the inotropic actions of certain catecholamines by U-0521 (3',4'-dihydroxy-alpha-methyl propiophenone).

Authors:  R E Giles; J W Miller
Journal:  J Pharmacol Exp Ther       Date:  1967-07       Impact factor: 4.030

9.  The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: A novel catechol amine uptake process.

Authors:  L L Iversen
Journal:  Br J Pharmacol Chemother       Date:  1965-08

10.  Effect of cocaine and related drugs on the uptake of noradrenaline by heart and spleen.

Authors:  E MUSCHOLL
Journal:  Br J Pharmacol Chemother       Date:  1961-06
View more
  6 in total

1.  Postsynaptic alpha-adrenoceptor reserve and the shift of the concentration-response curves to the right, as caused by the irreversible alpha-adrenoceptor antagonist phenoxybenzamine.

Authors:  S Guimarães; M Q Paiva
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

2.  The extraneuronal compartments for the distribution of isoprenaline in the rat heart.

Authors:  U Trendelenburg; H Fleig; L J Bryan; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

3.  A comparative study of the uptake and metabolism of noradrenaline and adrenaline by the isolated saphenous vein of the dog.

Authors:  M Q Paiva; S Guimarães
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-07       Impact factor: 3.000

4.  A study of the adrenoceptor-mediated feedback mechanism by using adrenaline as a false transmitter.

Authors:  S Guimarães; F Brandão; M Q Paiva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-11       Impact factor: 3.000

5.  Effect of catechol-O-methyl-transferase (COMT) inhibition on the vascular and metabolic responses to noradrenaline, isoprenaline and sympathetic nerve stimulation in canine subcutaneous adipose tissue.

Authors:  E Belfrage; B B Fredholm; S Rosell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

6.  Intra- and extraneuronal metabolism of 5-hydroxytryptamine in the isolated saphenous vein of the dog.

Authors:  M Q Paiva; M Caramona; W Osswald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.